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OBJECTIVES We studied the clinical characteristics and molecular background underlying a severe
phenotype of long QT syndrome (LQTS).
BACKGROUND Mutations of cardiac ion channel genes cause LQTS, manifesting as increased risk of
ventricular tachycardia and sudden death.
METHODS We studied two siblings showing prolonged QT intervals corrected for heart rate (QTc), their
asymptomatic parents with only marginally prolonged QTc intervals and their family
members. The potassium channel gene HERG was screened for mutations by deoxyribonu-
cleic acid sequencing, and the electrophysiologic consequences of the mutation were studied
in vitro using the whole-cell patch-clamp technique.
RESULTS A novel missense mutation (L552S) in the HERG channel, present in the homozygous state
in the affected siblings and in the heterozygous state in their parents, as well as in 38
additional subjects from six LQTS families, was identified. One of the homozygous siblings
had 2:1 atrioventricular block immediately after birth, and died at the age of four years after
experiencing unexplained hypoglycemia. The other sibling had an episode of torsade de
pointes at the age of two years. The mean QTc interval differed significantly (p , 0.001)
between heterozygous symptomatic mutation carriers (500 6 59 ms), asymptomatic mutation
carriers (452 6 34 ms) and noncarriers (412 6 23 ms). When expressed in vitro, the
HERG-L552S formed functional channels with increased activation and deactivation rates.
CONCLUSIONS Our data demonstrate that homozygosity for a HERG mutation can cause a severe cardiac
repolarization disorder without other phenotypic abnormalities. Absence of functional
HERG channels appears to be one cause for intrauterine and neonatal bradycardia and 2:1
atrioventricular block. (J Am Coll Cardiol 2000;35:1919–25) © 2000 by the American
College of Cardiology
The long QT syndrome (LQTS) is an inherited cardiac
channelopathy typically manifesting with ventricular tachy-
cardias, such as torsade de pointes, syncopal attacks and
sudden death at a young age (1). The clinical phenotype is
due to distorted myocardial repolarization and varies mark-
edly both within affected families and between families (2).
On the basis of inheritance and phenotypic characteristics,
LQTS was originally subclassified into an autosomal dom-
inant form (Romano-Ward syndrome) (3,4) and a rare and
more malignant recessive form associated with congenital
deafness (Jervell and Lange-Nielsen syndrome) (5). Recent
molecular genetic studies have revealed that these two
diseases are, in fact, allelic, resulting from mutations of two
potassium channel genes—KVLQT1 and minK (6–10).
The KVLQT1 and minK proteins co-assemble to form the
slowly activating delayed rectifier potassium (K1) channel
(IKs) present in cardiac myocytes and the inner ear (11,12).
In addition, mutations of the potassium channel gene
HERG (13) or sodium channel gene SCN5A (14) are
established causes of Romano-Ward syndrome. The
HERG gene encodes an alpha subunit of a voltage-gated,
rapidly activating delayed rectifier potassium channel that
induces significant repolarizating current IKr in cardiac
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myocytes (15). Until now, mutations of the HERG gene
have been reported in heterozygous patients only.
The LQTS displays marked heterogeneity at the molec-
ular level, and typically each family is affected by a unique
mutation of a particular ion channel gene. In the present
study, we describe the occurrence and molecular character-
istics of an apparent founder mutation of the HERG gene,
designated as HERG-Fin, which manifests both in the
heterozygous and homozygous state in the Finnish popula-
tion. Our data demonstrate that homozygosity for a HERG
mutation causes a severe cardiac repolarization disorder
without other phenotypic abnormalities. The prevalence of
the HERG-Fin mutation defines a milieu in which the role
of genetic and extrinsic factors, as modifiers of the LQTS
phenotype, can be effectively examined.
METHODS
Patients and control subjects. The proband in family
041090 was a 10-year-old girl (Fig. 1; III/5) who had
experienced tachycardia at the age of two years. Her younger
sister (Fig. 1; III/6) had intrauterine bradycardia and a
prolonged QT interval immediately after birth, and she died
at the age of four years. The paternity in the index family
was tested using highly polymorphic microsatellite markers,
and subject II/8 was interpreted to be father of both III/5
and III/6.
The individuals originally chosen as probands (n 5 88) to
search for ion channel mutations underlying LQTS were all
of Finnish origin, had LQTS without deafness and a
prolonged QT interval corrected for heart rate (QTc)
(.440 ms) and were symptomatic. Although they origi-
nated from different parts of the country, most of them were
from Eastern Finland. Specific mutations in the KVLQT1
gene have been characterized in 30% of Finnish subjects
with LQTS (16,17), but the disease-causing mutation is still
unknown in 57 probands. Informed consent was obtained
from all patients, and the study was approved by the Ethical
Review Committee of the University of Helsinki. Control
deoxyribonucleic acid (DNA) samples were obtained from
100 apparently healthy adult individuals.
The QT interval, defined according to the tangent
method, was presented as the mean value of two consecutive
QRST complexes, usually in lead II, and corrected for heart
rate (QTc) according to Bazett’s formula. Five symptomatic
and five asymptomatic heterozygous carriers underwent an
exercise stress test, as described earlier (18).
Mutation and haplotype analyses. Genomic DNA was
extracted from peripheral leukocytes using standard meth-
ods. Exons 4 and 7 of the HERG gene were sequenced after
their amplification by polymerase chain reaction (PCR),
using primers 59-ACGACCACGTGCCTCTCCTCTC-39
and 59-GGCTGGGGCGGAACGGGTCC-39 for exon 4
(19) and primers 59-TGCCCCATCAACGGATGTGC-39
and 59-GCCCGCCCCTGGGCACACTCA-39 for exon 7
(13). The PCR reactions were performed in a standard way
(16), and DNA sequencing was carried out using the dye
terminator, cycle-sequencing procedure and the ABI Prism
377 automatic DNA sequencer (PE Biosystems, Foster City,
California). A comparison of the HERG sequence with its
homologues was performed using the BLAST2 sequence
alignment program. The nucleotide numbering in the HERG
gene is started from the initiation methionine.
Abbreviations and Acronyms
DNA 5 deoxyribonucleic acid
EAD 5 early afterdepolarization
IKr 5 rapidly activated delayed rectifier potassium
channel
IKs 5 slowly activated delayed rectifier potassium
channel
LQTS 5 long QT syndrome
LQT2 5 type 2 long QT syndrome
PCR 5 polymerase chain reaction
PIRA 5 primer-induced restriction assay
QTc 5 QT interval corrected for heart rate
Figure 1. Compound pedigree of families 041 and 090. Index family (referred to as 041090 in text) consists of subjects II/8, II/13, III/5,
III/6 and III/7. Available corrected QT values (QTc, in ms) are shown under individual symbols. The medication may have affected the
QTc values of subjects I/2 and I/4. In addition, subject II/3 has left bundle branch block in the electrocardiogram (ECG), which prolongs
the QTc interval (values shown in parentheses). Neither the sample for DNA analysis nor the ECG was available from subjects marked
by an asterisk. Open circles/squares 5 female/male mutation noncarriers; half-filled symbols 5 L552S heterozygotes; and filled
symbols 5 L552S homozygotes.
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A primer-induced restriction assay (PIRA) was applied to
develop a simple and specific test for the detection of the
L552S mutation, essentially as described earlier (16). In
PCR, the PIRA-primer 59-ACGGCGCGGCCGTG-
CTGTCCT-39 was used as the forward primer and 59-
CAGCCAGCCGATGCGTGAGTC-39 as the reverse
primer. The 125–base pair PCR amplicon was digested
with the enzyme Mnl I (New England Biolabs, Beverly,
Massachusetts), with subsequent analysis of the PCR prod-
ucts by 12% polyacrylamide gel electrophoresis. The mis-
match in the PIRA-primer generates an extra Mnl I restric-
tion site in the PCR product of the mutant allele, thus
permitting its separation from the normal allele.
Four highly polymorphic microsatellite markers,
D7S505, D7S1826, D7S688 and D7S483, flanking the
HERG gene were used for haplotype analysis. After PCR,
the amplified fragments were separated using the ABI
Prism 377 automatic DNA sequencer (PE Biosystems) and
analyzed with the Genotyper program (PE Biosystems).
Functional expression of the mutant and wild type
HERG channels in COS7 cells. The HERG comple-
mentary DNA (cDNA) (U04270) in pcDNA3 plasmid was
kindly provided by Dr. Gail Robertson. The in vitro
mutagenesis was performed using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, California).
Transfections were made using the Effectene Transfection
Reagent (Qiagen, Valencia, California). An enhanced green
fluorescent protein plasmid was transfected with experimen-
tal constructs to identify the transfected cells. Whole-cell
membrane currents were measured using an EPC-9 ampli-
fier and Pulse/Pulsefit software (HEKA, Lambrecht, Ger-
many). The extracellular solution used in the recordings
contained (in mmol/liter): NaCl 150, KCl 5.4, CaCl2 1.8,
MgCl2 1 and HEPES 5 (pH 7.4 with NaOH), and the
recording pipettes were filled with a solution containing (in
mmol/liter): KCl 150, MgCl2 2, Bapta 10 and HEPES 10
(pH 7.2 with KOH). The recordings were made 48 to 72 h
after transfection. The activation and deactivation rates (tact
and tdeact) were calculated by fitting a single exponential to
the activation and tail currents. The half-activation voltage
(V0.5) was calculated from the immediate tail currents at
260 mV using the Bolzmann equation:
I 5
Imax
1 1 e(V2V0.5)/k
Statistical analysis. All data are presented as the mean
value 6 SD for clinical analysis and the mean value 6 SEM
for electrophysiologic measurements. Analysis of variance
was used to compare data between the different groups. A p
value ,0.05 was considered statistically significant.
RESULTS
Phenotypic characteristics of the index family. A family
(pedigree 041090, Fig. 1) with two severely affected children
but phenotypically normal parents was examined for the first
time in 1992. The proband was a girl who had an episode of
torsade de pointes tachycardia at the age of two years, which
coincided with the eruption of diabetes mellitus (III/5). Her
actual QT interval was 480 ms at the heart rate 100
beats/min (QTc 677 ms) (Fig. 2). Intravenous administra-
tion of lidocaine and magnesium did not abolish ventricular
arrhythmias, but the arrhythmias disappeared with amioda-
rone infusion. Since then, she has been treated with beta–
anti-adrenergic medication and insulin, with no recurrence
of symptoms (QTc 510 ms). Her audiogram showed normal
hearing bilaterally. Her sister (III/6) had intrauterine bra-
dycardia and was found to have a prolonged QTc interval
(513 ms) after birth. In addition, immediately after delivery,
2:1 atrioventricular block and frequent ventricular prema-
ture complexes occurred (Fig. 2) and were still present five
months after birth. Infusion of isoprenaline abolished these
ventricular arrhythmias during the early phase. The patient
was subsequently treated with propranolol and remained
symptomless (QTc 470 ms). However, at the age of four
years, an unexplained hypoglycemic episode occurred while
the patient had an acute respiratory infection. No medica-
tions, except propranolol, were used at the time of hypo-
glycemia. The severe illness led to aspiration and death soon
thereafter. The parents of the siblings had borderline QTc
intervals (436 and 441 ms, respectively) (Fig. 2) and were
free of any cardiac symptoms. Also, the youngest child of
the family (III/7) was phenotypically normal (QTc 420 ms).
Identification of the HERG-Fin mutation. The coding
sequence of the HERG gene (U04270) was directly se-
quenced, and a nucleotide change (T1655C) was detected in
exon 7 (data not shown). This mutation is predicted to
result in substitution of a conserved leucine by serine at
amino acid position 552, located in the cytoplasmic end of
the transmembrane domain S5 of the HERG subunit. The
L552S mutation was present in a heterozygous state in
DNA samples of both the father and mother of the family
041090 and in a homozygous state in DNA samples of the
two affected daughters (Fig. 1). In addition, the mutation
was present in the heterozygous form in four other families.
Altogether, the L552S mutation was found in the heterozy-
gous form in 40 individuals, but it was absent in 63
unaffected family members and in all 100 control subjects.
Six carriers of the L552S mutation (designated as
HERG-Fin) of the 88 unrelated Finnish LQTS probands
correspond to a prevalence rate of 7% for this mutation
among Finnish LQTS families. Four microsatellite markers
adjacent to the HERG gene locus were analyzed in all
families to construct disease-associated haplotypes; a com-
mon haplotype was present in all affected probands. The
affected grandparents of the homozygous individuals origi-
nated from the same commune in Lapland, whereas the
place of birth of the other ancestors was in Eastern Finland.
Clinical characteristics of the HERG-Fin mutation car-
riers. Ten of the 35 heterozygous carriers of the HERG-
Fin mutation were symptomatic and 25 were asymptomatic.
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Ninety percent of the former patients had their symptoms at
rest, whereas there was only one patient in whom concom-
itant physical exercise was associated with a syncopal spell.
There was no instance of an association of a QT-prolonging
drug therapy with cardiac events. In one heterozygous
carrier, failure with beta–anti-adrenergic medication led to
implantation of a cardiac defibrillator.
The mean QTc value of nonaffected family members
(412 6 23 ms [range 370 to 475]) was significantly lower than
that of all heterozygotes (466 6 47 ms [range 400 to 620]; p ,
0.001) (Fig. 3). There was a trend toward a longer mean QTc
interval in heterozygous female mutation carriers (471 6
47 ms) than in male carriers (447 6 43 ms; p 5 NS). Mean
QT and QTc intervals of the symptomatic mutation carriers
were significantly (p , 0.001) longer than those of asymptom-
atic carriers. However, there was a marked female preponder-
ance among the symptomatic carriers (Table 1). None of the
mutation carriers included in these calculations had any med-
ication or other disease, except for the ventricular repolarization
abnormality at the moment of QTc measurement.
Figure 2. Electrocardiographic recordings (leads V1 to V6, paper speed 50 mm/s) of the index family. Subjects III/5 and III/6 (recordings
at birth and three years of age while on propranolol) were subsequently shown to be homozygous for the L552S mutation.
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In ergometer exercise testing, the mean maximal heart
rate was 99% of the expected age-related maximal heart rate
in both the symptomatic (n 5 5) and asymptomatic (n 5 5)
heterozygous carriers studied. Three of five symptomatic
carriers exhibited frequent ventricular premature complexes,
whereas none of the asymptomatic carriers had any arrhyth-
mias during the exercise stress test (data not shown).
Functional properties of the L552S mutation in vitro.
To characterize the properties of the L552S mutation in
vitro, it was introduced into a HERG-wild type (HERG-
wt) cDNA construct (HERG-L552S). The HERG-wt and
HERG-L552S were transiently expressed in COS7 cells
and used in whole-cell, patch-clamp experiments. The
HERG-L552S construct produced functional channels in
COS7 cells, with robust currents similar in amplitude to
those generated by the HERG-wt construct (Fig. 4). The
current–voltage relationships of the peak tail currents were
slightly different for HERG-wt and HERG-L552S, and
HERG-L552S displayed a marked increase in the rate of
activation and deactivation (Fig. 4). The activation rate
constants (tact) at an activation voltage of 0 mV were 891 6
116 ms and 151 6 28 ms for HERG-wt and HERG-
L552S, respectively, whereas the corresponding deactivation
rate constants at 260 mV (tdeact) were 623 6 101 ms and
120 6 19 ms, respectively (n 5 8). The HERG-L552S was
activated at slightly lower voltages than was HERG-wt.
The half-activation voltage (V0.5) was 25.4 6 2.1 mV for
HERG-wt and 213.8 6 1.6 mV for HERG-L552S. The
increase in the HERG-L552S deactivation rate is expected
to result in a decreased channel activity at the end of the
cardiac action potential repolarization, making the cell more
vulnerable to early afterdepolarizations (EADs).
DISCUSSION
The clinical presentation of a homozygous state in type 2
long QT syndrome (LQT2) is described for the first time,
to our knowledge. Although a novel missense mutation of
the HERG potassium channel gene was found to cause
typical Romano-Ward syndrome in its heterozygous carri-
ers, homozygosity for this mutation resulted in a severe
cardiac phenotype, similar to that described earlier for
homozygous KVLQT1 and minK mutation carriers (Jervell
and Lange-Nielsen syndrome), but no other abnormalities.
The present study also suggests that homozygosity for a
HERG channel defect may be associated with abnormalities
in atrioventricular conduction and glucose homeostasis.
The HERG-Fin mutation affects a structure conserved
in evolution and important in channel deactivation. The
HERG-Fin (L552S) mutation is located in the intracellular
amino terminal end of the S5 domain. This region, together
with the pore and S4 domains, appears to be the most
conserved part of the eag gene family (20). Furthermore,
leucine 552 is highly conserved in the homologous genes of
several distinct species, including those of Drosophila, Mus
musculus, Rattus norwegicus, Oryctolagus cuniculus and Bos
taurus, as well as in genes of the Shaker gene family.
Figure 3. Distribution of corrected QT intervals (QTc, in ms) of
L552S homozygotes, L552S heterozygotes (symptomatic shown as
triangles and asymptomatic as circles) and L552S noncarriers.
Only the QTc values of individuals with no medication are
included.
Table 1. Comparison of Clinical and Electrocardiographic Characteristics of Symptomatic and Asymptomatic L552S Mutation
Carriers and Noncarriers
Noncarriers
(n 5 43)
Heterozygous Carriers
Asymptomatic
(n 5 25)
Symptomatic
(n 5 10)
p Value
(ANOVA)
Mean age (years) 36 6 16 26 6 14 40 6 17 —
Age range (years) 7–70 2–52 15–64 —
Men/women 21/22 7/18 1/9 —
Rest heart rate (beats/min) 67 6 14 79 6 21 67 6 16 , 0.05*
QT interval (ms), lead II 394 6 42 400 6 45 482 6 86 , 0.001†
QTc interval (ms), lead II 412 6 23 452 6 34 500 6 59 , 0.001‡
*Noncarriers versus asymptomatic carriers: p , 0.05; symptomatic versus asymptomatic carriers: p , 0.05. †Noncarriers versus symptomatic carriers: p , 0.001; symptomatic
versus asymptomatic carriers: p , 0.001. ‡Between all groups: p , 0.001.
Data are presented as the mean value 6 SD for clinical variables and the mean value 6 SEM for electrophysiological variables.
ANOVA 5 analysis of variance; QTc 5 QT interval corrected for heart rate.
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In whole-cell patch-clamp experiments, the L552S mu-
tation displayed a marked increase in both activation and
deactivation rates, as compared with wild type channels.
The amplitude and timing of the HERG channel conduc-
tance during the cardiac action potential are critically
dependent on the fast inactivation and slow deactivation
properties of the channel. During the cardiac action poten-
tial, the rapid inactivation properties of HERG result in
only a small conductance at depolarized membrane poten-
tials, and the conductance reaches a maximum at the end of
the repolarization phase at voltages well below 260 mV
(21). Although the peak HERG current occurs during the
action potential repolarization, the HERG conductance
normally peaks during the terminal action potential repo-
larization phase, effectively preventing the occurrence of
EADs. An increase in the HERG deactivation rate, as seen
here for the HERG-Fin mutation, is expected to decrease
the HERG conductance during terminal action potential
repolarization. This could prolong the repolarization and
reduce the stability of the membrane in the face of depo-
larizing currents, subjecting the cell to EADs.
In voltage-gated potassium channels Kv2.1 and Kv3.1,
specific residues in the S5 region are shown to regulate
deactivation of the channel (22). The S5 domain (codons 549
to 572) of the HERG subunit could have a similar function, as
the adjacent S4–S5 linker, corresponding to amino acids
539–548, is suggested to interact directly with the N-terminus
of the protein, and thus modulate both deactivation and
inactivation of the HERG channel (23). Indeed, our present
data show that the amino acid at position 552 is important in
channel deactivation, suggesting that the intracellular NH2
domain may also interact with L552 when the channel is in the
open conformation (23).
Phenotype in HERG-Fin homozygotes and heterozy-
gotes and influence of gender. Siblings homozygous for
HERG-Fin had markedly prolonged QTc intervals and
experienced ventricular tachycardias at a very young age.
The cardiac phenotype therefore resembles that present in
the Jervell and Lange-Nielsen syndrome. A neonatal bra-
dycardia resulting from 2:1 atrioventricular block was ob-
served in one of the homozygous siblings. Such arrhythmias
have been observed infrequently in neonates, often with a
poor prognosis (24). An interesting feature in both homozy-
gous patients was the association between cardiac events and
disturbances of serum glucose levels. Although the patho-
physiologic relation between the HERG channel defect and
disorder of glucose homeostasis, if any, remains to be
explored, it is tempting to suggest that the arrhythmias of
the HERG-Fin homozygotes were related to rapid changes
in serum potassium concentration, possibly arising from an
imbalance between circulating insulin and glucose levels.
Although there appear to be no data on expression of the
HERG gene in the inner ear, the present findings suggest
that the HERG channel, unlike KVLQT1 and minK, has
no critical auditory function.
The spectrum of the phenotype of the heterozygous
HERG-Fin carriers was wide, ranging from asymptomatic
patients to those who had experienced recurrent syncopal
spells. It is of particular interest that only one heterozygous
individual experienced syncopes related to physical exercise,
whereas the symptoms of the others occurred at rest. The
low incidence of exercise-related cardiac events in this group
of patients with LQT2 is in congruence with our previous
findings demonstrating that the QT interval of the patients
with LQT2 shortens efficiently during exercise-induced
acceleration of heart rate (18).
In the present series of genetically homogeneous patients
with LQTS, all but one of the 10 symptomatic patients were
women. Our data are in accordance with those derived from
the LQTS International Registry (25,26). Earlier findings
in acquired LQTS due to pharmacologic blockade of
HERG, likewise, suggest that women are more prone to
QT interval prolongation and risk of cardiac arrhythmias
than are men (27,28). The proarrhythmic effect of female
sex hormone in the presence of IKr-blocking agents has also
been demonstrated in animal studies (27,29).
Evidence for a HERG-Fin founder gene. Six apparently
unrelated families of Finnish origin were shown to carry the
identical HERG-Fin mutation. We propose that this mu-
tation has been enriched in Finland as a consequence of a
founder gene effect, by virtue of the relatively young age of
the Finnish population and its historically isolated nature
Figure 4. In vitro expression of the L552S mutation in COS7 cells. Whole-cell, patch-clamp recordings from a cell transfected with
HERG-wt plasmid and with HERG-L552S plasmid. Note the rapid onset and rapid decay of the HERG-L552S currents. The common
voltage protocol is shown on the right.
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owing to geographic, cultural and linguistic reasons (30).
Ancestors of all families appeared to be clustered in North-
ern and Eastern Finland. On the basis of studies on
Y-chromosomal haplotypes, the province of Lapland is
supposed to be a genetic isolate possibly inhabited by people
living in Sweden about 2,000 years ago (31,32). The
geographic distribution of affected grandparents, combined
with Finnish population history, predicts a founder gene
effect that was confirmed by haplotype analysis. Previously,
a founder mutation of the KVLQT1 gene was tentatively
suggested to occur in a South African population (33).
Clinical implications and conclusions. This study de-
scribes the first patients with LQTS who were homozygous
for a HERG potassium channel gene mutation, presenting
with a severe cardiac phenotype but no other phenotypic
characteristics. Our findings, based on a genetically homoge-
neous cohort of patients with LQTS, also suggest that female
gender may be an additional risk factor for QT prolongation
and possibly for occurrence of cardiac events in LQT2.
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